The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
James D. Bearden - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased Libido north central cancer treatment group protocol n02c3
Journal of the National Cancer Institute, 2008Co-Authors: Debra L. Barton, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, Jeff A Sloan, James D. BeardenAbstract:BACKGROUND Decreased Libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased Libido among estrogen-replete women who report low Libido. METHODS In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or Libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. RESULTS We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P<.001 for all). However, the average intrapatient Libido change from baseline to weeks 4 and 8 was similar on both arms. CONCLUSION Increased testosterone level did not translate into improved Libido, possibly because women on this study were estrogen depleted.
-
Transdermal testosterone in female cancer survivors with decreased Libido
Journal of Clinical Oncology, 2006Co-Authors: Debra L. Barton, Charles L. Loprinzi, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, James D. BeardenAbstract:8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as Libido. Studies of transdermal testosterone have shown benefit in enhancing Libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase Libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, Libido, was measured via the desire subscales of the Changes in Sexual Function...
Debra L. Barton - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased Libido north central cancer treatment group protocol n02c3
Journal of the National Cancer Institute, 2008Co-Authors: Debra L. Barton, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, Jeff A Sloan, James D. BeardenAbstract:BACKGROUND Decreased Libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased Libido among estrogen-replete women who report low Libido. METHODS In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or Libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. RESULTS We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P<.001 for all). However, the average intrapatient Libido change from baseline to weeks 4 and 8 was similar on both arms. CONCLUSION Increased testosterone level did not translate into improved Libido, possibly because women on this study were estrogen depleted.
-
Transdermal testosterone in female cancer survivors with decreased Libido
Journal of Clinical Oncology, 2006Co-Authors: Debra L. Barton, Charles L. Loprinzi, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, James D. BeardenAbstract:8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as Libido. Studies of transdermal testosterone have shown benefit in enhancing Libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase Libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, Libido, was measured via the desire subscales of the Changes in Sexual Function...
-
Libido as part of sexuality in female cancer survivors.
Oncology nursing forum, 2004Co-Authors: Debra L. Barton, Mary B. Wilwerding, Lisa A. Carpenter, Charles L. LoprinziAbstract:PURPOSE/OBJECTIVES To present the state of knowledge and a suggested program of research related to one part of sexual functioning in female cancer survivors: Libido. DATA SOURCES Journal articles, monographs, and book chapters. DATA SYNTHESIS Sexuality is a broadly defined term with many components. Libido is a component of sexuality and is reviewed with respect to definition, physiology, and measurement. Evidence-based interventions also are discussed. CONCLUSIONS Most of the evidence related to enhancing Libido involves testosterone, but this has not been tested in cancer survivors. Several clinical questions are yet to be answered regarding physiology as well as nonpharmacologic and pharmacologic interventions for enhancing Libido. IMPLICATIONS FOR NURSING Nurse researchers could add much to the evidence base on interventions for improving Libido and, subsequently, sexual health. Implementing behavioral interventions to enhance Libido would be an appropriate nursing function.
Bruce R. Carr - One of the best experts on this subject based on the ideXlab platform.
-
Has testosterone passed the test in premenopausal women with low Libido? A systematic review.
International journal of women's health, 2016Co-Authors: Beverly G. Reed, Laurice Bou Nemer, Bruce R. CarrAbstract:BACKGROUND There are limited evaluation and treatment options for low Libido in premenopausal women. This review sought to evaluate the available evidence supporting the evaluation of testosterone serum levels and testosterone treatment of premenopausal women with low Libido. METHODS MEDLINE, PubMed, and ClinicalTrials.gov were searched for articles that referenced the evaluation of testosterone serum level and/or testosterone treatment on premenopausal women with low Libido from 1995 to 2015. Additional references were obtained from the reference sections of other papers and from peer review. Studies that included only postmenopausal women were excluded. A total of 13 studies were reviewed in detail. Nine studies examined the relationship between testosterone serum levels and sexuality, an additional three studies examined the effect of testosterone treatment on premenopausal women with low Libido, and one study examined both the topics. RESULTS Six of the ten testosterone serum evaluation studies failed to show a significant association between testosterone serum level and Libido. Only one out of four studies examining testosterone treatment in premenopausal women was able to show any clear improvement in Libido; however, the effect was limited to only the intermediate dose of testosterone, with the low and high doses of testosterone not producing any effect. CONCLUSION The currently available evidence does not support testosterone serum evaluation or treatment in premenopausal women with low Libido. Hence, further studies are warranted.
Albert M. Bernath - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased Libido north central cancer treatment group protocol n02c3
Journal of the National Cancer Institute, 2008Co-Authors: Debra L. Barton, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, Jeff A Sloan, James D. BeardenAbstract:BACKGROUND Decreased Libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased Libido among estrogen-replete women who report low Libido. METHODS In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or Libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. RESULTS We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P<.001 for all). However, the average intrapatient Libido change from baseline to weeks 4 and 8 was similar on both arms. CONCLUSION Increased testosterone level did not translate into improved Libido, possibly because women on this study were estrogen depleted.
-
Transdermal testosterone in female cancer survivors with decreased Libido
Journal of Clinical Oncology, 2006Co-Authors: Debra L. Barton, Charles L. Loprinzi, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, James D. BeardenAbstract:8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as Libido. Studies of transdermal testosterone have shown benefit in enhancing Libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase Libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, Libido, was measured via the desire subscales of the Changes in Sexual Function...
Ernie P. Balcueva - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased Libido north central cancer treatment group protocol n02c3
Journal of the National Cancer Institute, 2008Co-Authors: Debra L. Barton, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, Jeff A Sloan, James D. BeardenAbstract:BACKGROUND Decreased Libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased Libido among estrogen-replete women who report low Libido. METHODS In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or Libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. RESULTS We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P<.001 for all). However, the average intrapatient Libido change from baseline to weeks 4 and 8 was similar on both arms. CONCLUSION Increased testosterone level did not translate into improved Libido, possibly because women on this study were estrogen depleted.
-
Transdermal testosterone in female cancer survivors with decreased Libido
Journal of Clinical Oncology, 2006Co-Authors: Debra L. Barton, Charles L. Loprinzi, Donald B. Wender, Robert J. Dalton, Ernie P. Balcueva, Pamela J. Atherton, Albert M. Bernath, Wanda L. Dekrey, T. Larson, James D. BeardenAbstract:8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as Libido. Studies of transdermal testosterone have shown benefit in enhancing Libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase Libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, Libido, was measured via the desire subscales of the Changes in Sexual Function...